Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2024 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2024 Earnings Call Transcript November 4, 2024Supernus Pharmaceuticals, Inc. beats earnings expectations.
Supernus Pharmaceuticals Inc. (SUPN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 5,096,000 | $158,893,280 | -4% | 2.54% |
| 2. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,937,930 | $60,424,657 | -1% | 0.28% |
| 3. | Renaissance Technologies Jim Simons | 1,728,622 | $53,898,434 | +3% | 0.08% |
| 4. | D E Shaw D. E. Shaw | 408,788 | $12,746,010 | +41% | 0.01% |
| 5. | Millennium Management Israel Englander | 252,743 | $7,880,527 | +57% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.39 | 7,200 | Officer, Director | 465,141 | 2019-08-23 | Filing | |
| $5.65 | 15,000 | Director | 25,000 | 2013-03-22 | Filing | |
| $5.26 | 10,000 | Director | 10,000 | 2013-03-20 | Filing | |
| $5.20 | 5,000 | Director | 5,000 | 2013-03-20 | Filing | |
| $5.17 | 5,000 | Director | 5,000 | 2013-03-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.68 | 12,745 | Officer | 9,679 | 2024-12-03 | Filing | |
| $36.68 | 8,750 | Officer | 9,679 | 2024-12-03 | Filing | |
| $36.24 | 10,700 | Director | 130,275 | 2024-11-11 | Filing | |
| $36.28 | 8,722 | Director | 28,395 | 2024-11-08 | Filing | |
| $36.30 | 10,787 | Director | 13,315 | 2024-11-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,382,770 | $300,477,364 | 0% | |
| 2. | 6,214,731 | $179,854,315 | 0% | |
| 3. | 2,737,716 | $79,230,000 | 0.09% | |
| 4. | 2,456,369 | $71,088,799 | 0.02% | |
| 5. | 2,062,326 | $59,683,714 | 0% |
News See All
Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug
Scout Investments, Inc, an affiliate of Carillon Tower Advisers, released the “Carillon Scout Small Cap Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2024 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2024 Earnings Call Transcript August 6, 2024Supernus Pharmaceuticals, Inc. misses on earnings expectations.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Supernus Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Corporate Insiders Are Selling These 10 Small-Cap Stocks
In this article, we will take a detailed look at Corporate Insiders Are Selling These 10 Small-Cap Stocks. For a quick overview of such stocks, read our article Corporate Insiders Are Selling These...
11 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Supernus Pharmaceuticals' Fourth Quarter and Full Year 2023 Financial Results Conference Call.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to Supernus Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode.
5 Best Small Cap Pharma Stocks to Buy
In this piece, we will take a look at the five best small cap pharma stocks to buy.